1. Home
  2. RLI vs LEGN Comparison

RLI vs LEGN Comparison

Compare RLI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLI Corp. (DE)

RLI

RLI Corp. (DE)

HOLD

Current Price

$62.33

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$18.05

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLI
LEGN
Founded
1965
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.9B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
RLI
LEGN
Price
$62.33
$18.05
Analyst Decision
Hold
Buy
Analyst Count
7
14
Target Price
$66.00
$63.46
AVG Volume (30 Days)
684.5K
2.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.21%
N/A
EPS Growth
16.84
N/A
EPS
4.37
N/A
Revenue
$1,882,448,000.00
N/A
Revenue This Year
N/A
$67.56
Revenue Next Year
$3.17
$43.20
P/E Ratio
$14.50
N/A
Revenue Growth
6.33
N/A
52 Week Low
$55.80
$16.24
52 Week High
$81.79
$45.30

Technical Indicators

Market Signals
Indicator
RLI
LEGN
Relative Strength Index (RSI) 55.97 42.85
Support Level $62.04 $16.24
Resistance Level $63.61 $23.68
Average True Range (ATR) 1.43 0.84
MACD 0.21 0.13
Stochastic Oscillator 67.03 12.06

Price Performance

Historical Comparison
RLI
LEGN

About RLI RLI Corp. (DE)

RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: